ArticleInternal medicine (Tokyo, Japan)2026
Influence of Daily Salt Intake on Blood Pressure and Atrial Natriuretic Peptide Levels in Patients Treated with Sacubitril/Valsartan.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective Sacubitril/valsartan combines the effects of angiotensin receptor blockers (ARBs) with increased atrial natriuretic peptide (ANP) levels through neprilysin inhibition. ANP has vasodilatory and natriuretic effects. ARB efficacy is diminished by high daily salt intake (HDSI) in hypertension; however, it is unclear whether HDSI similarly affects the efficacy of sacubitril/valsartan. We aimed to assess the effect of ANP on blood pressure (BP) in patients with hypertension and HDSI treated with sacubitril/valsartan. Methods Fifty consecutive patients with hypertension previously on ARBs were enrolled and switched to sacubitril/valsartan (200 mg). BP and ANP levels were measured at baseline and two weeks after initiation. DSI was calculated from spot urine samples at these time points. Patients were divided into HDSI and low DSI (LDSI) groups based on the median baseline DSI. Results All patients had chronic kidney disease. The baseline average systolic/diastolic BP was 151±11/89±16 mmHg. At follow-up, both groups showed significant absolute and percentage BP reductions, with no significant differences between the groups. The DSI levels obtained by urine tests were significantly higher in the HDSI group than in the LDSI group. ANP levels increased in both groups at follow-up and more significantly in the HDSI group than in the LDSI group (573±585 vs. 84±78 pg/mL, p<0.001; 144±98% vs. 35±28%, p<0.001). Conclusion Sacubitril/valsartan was effective in lowering BP not only in patients with lower salt intake but also in patients with higher salt intake. The notable medication-induced increase in ANP levels may contribute to BP reduction through vasodilatory and natriuretic actions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.